Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects
•Anti-SARS-CoV-2 serological assay correlation to live virus neutralization tests.•Antibodies levels were correlated to SARS-CoV-2 original and British variant strains.•A proportional increase in neutralizing activity and antibody concentration resulted.•Neutralizing antibodies detection is a good a...
Gespeichert in:
| Veröffentlicht in: | International immunopharmacology 2021-12, Vol.101 (Pt B), p.108215-108215, Article 108215 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 108215 |
|---|---|
| container_issue | Pt B |
| container_start_page | 108215 |
| container_title | International immunopharmacology |
| container_volume | 101 |
| creator | Cristiano, Antonio Nuccetelli, Marzia Pieri, Massimo Sarubbi, Serena Pelagalli, Martina Calugi, Graziella Tomassetti, Flaminia Bernardini, Sergio |
| description | •Anti-SARS-CoV-2 serological assay correlation to live virus neutralization tests.•Antibodies levels were correlated to SARS-CoV-2 original and British variant strains.•A proportional increase in neutralizing activity and antibody concentration resulted.•Neutralizing antibodies detection is a good alternative to virus neutralization tests.•A cut-off of 408.6 BAU/ml can identify subjects at low risk of infection.
A large number of immunoassays have been developed to detect specific anti-SARS-CoV-2 antibodies; however, not always they are functional to neutralize the virus. The reference test for the anti-spike neutralizing antibodies (nAbs) ability to counteract the viral infection is the virus neutralization test (VNT). Great interest is developing on reliable serological assays allowing antibodies concentration and antibody protective titer correlation. The aim of our study was to detect nAbs serum levels in paucisymptomatic, symptomatic and vaccinated subjects, to find a cut-off value able to protect from virus infection.
nAbs serum levels were detected by a competitive automated immunoassay, in association to VNT with the SARS-CoV-2 original and British variant strains.
The median nAbs concentrations were: 281.3 BAU/ml for paucisymptomatics; 769.4 BAU/ml for symptomatics; 351.65 BAU/ml for the vaccinated cohort; 983 BAU/ml considering only the second dose vaccinated individuals. The original strain VNT analysis showed 1:80 median neutralization titers in paucisymptomatic and vaccinated subjects; 1:160 in symptomatic patients; 1:160 in the second dose groups. The British variant VNT analysis showed lower neutralization titers in paucisymptomatic and vaccinated groups (1:40); the same titer in symptomatic patients (1:160); the second dose group confirmed the original strain titer (1:160).
In conclusion, our data showed optimal correlations with a proportional increase between neutralizing activity and antibody concentration, making nAbs detection a good alternative to virus neutralization assays, difficult to carry out in routine laboratories. Finally, ROC curve analysis established a cut-off of 408.6 BAU/ml to identify subjects with a low risk of infection. |
| doi_str_mv | 10.1016/j.intimp.2021.108215 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_2624986319</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567576921008511</els_id><sourcerecordid>2582812800</sourcerecordid><originalsourceid>FETCH-LOGICAL-c491t-8d7c7db01b8d4f242f12aba0483b0bf1c9de7dc39211670e3358976ae610240d3</originalsourceid><addsrcrecordid>eNp9Uk1v1DAQjRCIlsI_QMgSFy7ZepwPOxekavmqVKkSC71aju1dJkrsYDsrlV_FT8RlS2k5cPJo5s2beeNXFC-BroBCezqs0CWc5hWjDHJKMGgeFccguCiB0-ZxjpuWlw1vu6PiWYwDpTlfw9PiqKrbugNojoufGxv86Heo1UhUJiw3Z5835dpflYw4u6SgRvyBbve72HuDNhIVo9eoEnpHkicj7i3ZY1jiw45kYyIJkw2RoCPry6vzdyV0ZFaLxng9zclPmUSf3otzMaF1KQ9xhuyV1uhUsobEpR-sTvF58WSrxmhf3L4nxdcP77-sP5UXlx_P12cXpc7KUikM19z0FHph6i2r2RaY6hWtRdXTfgu6M5YbXXUMoOXUVlUjOt4q2wJlNTXVSfH2wDsv_WSNzjtlYXIOOKlwLb1C-bDi8Jvc-b0UteCcQyZ4c0sQ_Pcln0JOGLUdR-WsX6JkjWACmKA0Q1__Ax38ElyWJ1nL6k60FXQZVR9QOvgYg93eLQNU3lhCDvJgCXljCXmwRG57dV_IXdMfD_xVavM592iDjDp_gbYGQ764NB7_P-EXOUbOUQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2624986319</pqid></control><display><type>article</type><title>Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Cristiano, Antonio ; Nuccetelli, Marzia ; Pieri, Massimo ; Sarubbi, Serena ; Pelagalli, Martina ; Calugi, Graziella ; Tomassetti, Flaminia ; Bernardini, Sergio</creator><creatorcontrib>Cristiano, Antonio ; Nuccetelli, Marzia ; Pieri, Massimo ; Sarubbi, Serena ; Pelagalli, Martina ; Calugi, Graziella ; Tomassetti, Flaminia ; Bernardini, Sergio</creatorcontrib><description>•Anti-SARS-CoV-2 serological assay correlation to live virus neutralization tests.•Antibodies levels were correlated to SARS-CoV-2 original and British variant strains.•A proportional increase in neutralizing activity and antibody concentration resulted.•Neutralizing antibodies detection is a good alternative to virus neutralization tests.•A cut-off of 408.6 BAU/ml can identify subjects at low risk of infection.
A large number of immunoassays have been developed to detect specific anti-SARS-CoV-2 antibodies; however, not always they are functional to neutralize the virus. The reference test for the anti-spike neutralizing antibodies (nAbs) ability to counteract the viral infection is the virus neutralization test (VNT). Great interest is developing on reliable serological assays allowing antibodies concentration and antibody protective titer correlation. The aim of our study was to detect nAbs serum levels in paucisymptomatic, symptomatic and vaccinated subjects, to find a cut-off value able to protect from virus infection.
nAbs serum levels were detected by a competitive automated immunoassay, in association to VNT with the SARS-CoV-2 original and British variant strains.
The median nAbs concentrations were: 281.3 BAU/ml for paucisymptomatics; 769.4 BAU/ml for symptomatics; 351.65 BAU/ml for the vaccinated cohort; 983 BAU/ml considering only the second dose vaccinated individuals. The original strain VNT analysis showed 1:80 median neutralization titers in paucisymptomatic and vaccinated subjects; 1:160 in symptomatic patients; 1:160 in the second dose groups. The British variant VNT analysis showed lower neutralization titers in paucisymptomatic and vaccinated groups (1:40); the same titer in symptomatic patients (1:160); the second dose group confirmed the original strain titer (1:160).
In conclusion, our data showed optimal correlations with a proportional increase between neutralizing activity and antibody concentration, making nAbs detection a good alternative to virus neutralization assays, difficult to carry out in routine laboratories. Finally, ROC curve analysis established a cut-off of 408.6 BAU/ml to identify subjects with a low risk of infection.</description><identifier>ISSN: 1567-5769</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2021.108215</identifier><identifier>PMID: 34649115</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antibodies ; Antibodies, Neutralizing - blood ; Antibodies, Viral - blood ; Asymptomatic Infections ; COVID-19 ; COVID-19 - blood ; COVID-19 - immunology ; COVID-19 - prevention & control ; COVID-19 Vaccines ; Female ; Health risks ; Humans ; Immunoassay ; Immunoassays ; Infections ; Live VNT ; Male ; Middle Aged ; Neutralization ; Neutralization Tests ; Neutralizing ; SARS-CoV-2 - immunology ; SARS-CoV-2 neutralizing antibodies ; Serological immunoassay ; Serology ; Serum levels ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Strain analysis ; Vaccination ; Viral diseases ; Viral infections ; Viruses ; Young Adult</subject><ispartof>International immunopharmacology, 2021-12, Vol.101 (Pt B), p.108215-108215, Article 108215</ispartof><rights>2021 Elsevier B.V.</rights><rights>Copyright © 2021 Elsevier B.V. All rights reserved.</rights><rights>Copyright Elsevier BV Dec 2021</rights><rights>2021 Elsevier B.V. All rights reserved. 2021 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c491t-8d7c7db01b8d4f242f12aba0483b0bf1c9de7dc39211670e3358976ae610240d3</citedby><cites>FETCH-LOGICAL-c491t-8d7c7db01b8d4f242f12aba0483b0bf1c9de7dc39211670e3358976ae610240d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.intimp.2021.108215$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34649115$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cristiano, Antonio</creatorcontrib><creatorcontrib>Nuccetelli, Marzia</creatorcontrib><creatorcontrib>Pieri, Massimo</creatorcontrib><creatorcontrib>Sarubbi, Serena</creatorcontrib><creatorcontrib>Pelagalli, Martina</creatorcontrib><creatorcontrib>Calugi, Graziella</creatorcontrib><creatorcontrib>Tomassetti, Flaminia</creatorcontrib><creatorcontrib>Bernardini, Sergio</creatorcontrib><title>Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>•Anti-SARS-CoV-2 serological assay correlation to live virus neutralization tests.•Antibodies levels were correlated to SARS-CoV-2 original and British variant strains.•A proportional increase in neutralizing activity and antibody concentration resulted.•Neutralizing antibodies detection is a good alternative to virus neutralization tests.•A cut-off of 408.6 BAU/ml can identify subjects at low risk of infection.
A large number of immunoassays have been developed to detect specific anti-SARS-CoV-2 antibodies; however, not always they are functional to neutralize the virus. The reference test for the anti-spike neutralizing antibodies (nAbs) ability to counteract the viral infection is the virus neutralization test (VNT). Great interest is developing on reliable serological assays allowing antibodies concentration and antibody protective titer correlation. The aim of our study was to detect nAbs serum levels in paucisymptomatic, symptomatic and vaccinated subjects, to find a cut-off value able to protect from virus infection.
nAbs serum levels were detected by a competitive automated immunoassay, in association to VNT with the SARS-CoV-2 original and British variant strains.
The median nAbs concentrations were: 281.3 BAU/ml for paucisymptomatics; 769.4 BAU/ml for symptomatics; 351.65 BAU/ml for the vaccinated cohort; 983 BAU/ml considering only the second dose vaccinated individuals. The original strain VNT analysis showed 1:80 median neutralization titers in paucisymptomatic and vaccinated subjects; 1:160 in symptomatic patients; 1:160 in the second dose groups. The British variant VNT analysis showed lower neutralization titers in paucisymptomatic and vaccinated groups (1:40); the same titer in symptomatic patients (1:160); the second dose group confirmed the original strain titer (1:160).
In conclusion, our data showed optimal correlations with a proportional increase between neutralizing activity and antibody concentration, making nAbs detection a good alternative to virus neutralization assays, difficult to carry out in routine laboratories. Finally, ROC curve analysis established a cut-off of 408.6 BAU/ml to identify subjects with a low risk of infection.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies</subject><subject>Antibodies, Neutralizing - blood</subject><subject>Antibodies, Viral - blood</subject><subject>Asymptomatic Infections</subject><subject>COVID-19</subject><subject>COVID-19 - blood</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines</subject><subject>Female</subject><subject>Health risks</subject><subject>Humans</subject><subject>Immunoassay</subject><subject>Immunoassays</subject><subject>Infections</subject><subject>Live VNT</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neutralization</subject><subject>Neutralization Tests</subject><subject>Neutralizing</subject><subject>SARS-CoV-2 - immunology</subject><subject>SARS-CoV-2 neutralizing antibodies</subject><subject>Serological immunoassay</subject><subject>Serology</subject><subject>Serum levels</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Strain analysis</subject><subject>Vaccination</subject><subject>Viral diseases</subject><subject>Viral infections</subject><subject>Viruses</subject><subject>Young Adult</subject><issn>1567-5769</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9Uk1v1DAQjRCIlsI_QMgSFy7ZepwPOxekavmqVKkSC71aju1dJkrsYDsrlV_FT8RlS2k5cPJo5s2beeNXFC-BroBCezqs0CWc5hWjDHJKMGgeFccguCiB0-ZxjpuWlw1vu6PiWYwDpTlfw9PiqKrbugNojoufGxv86Heo1UhUJiw3Z5835dpflYw4u6SgRvyBbve72HuDNhIVo9eoEnpHkicj7i3ZY1jiw45kYyIJkw2RoCPry6vzdyV0ZFaLxng9zclPmUSf3otzMaF1KQ9xhuyV1uhUsobEpR-sTvF58WSrxmhf3L4nxdcP77-sP5UXlx_P12cXpc7KUikM19z0FHph6i2r2RaY6hWtRdXTfgu6M5YbXXUMoOXUVlUjOt4q2wJlNTXVSfH2wDsv_WSNzjtlYXIOOKlwLb1C-bDi8Jvc-b0UteCcQyZ4c0sQ_Pcln0JOGLUdR-WsX6JkjWACmKA0Q1__Ax38ElyWJ1nL6k60FXQZVR9QOvgYg93eLQNU3lhCDvJgCXljCXmwRG57dV_IXdMfD_xVavM592iDjDp_gbYGQ764NB7_P-EXOUbOUQ</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Cristiano, Antonio</creator><creator>Nuccetelli, Marzia</creator><creator>Pieri, Massimo</creator><creator>Sarubbi, Serena</creator><creator>Pelagalli, Martina</creator><creator>Calugi, Graziella</creator><creator>Tomassetti, Flaminia</creator><creator>Bernardini, Sergio</creator><general>Elsevier B.V</general><general>Elsevier BV</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20211201</creationdate><title>Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects</title><author>Cristiano, Antonio ; Nuccetelli, Marzia ; Pieri, Massimo ; Sarubbi, Serena ; Pelagalli, Martina ; Calugi, Graziella ; Tomassetti, Flaminia ; Bernardini, Sergio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c491t-8d7c7db01b8d4f242f12aba0483b0bf1c9de7dc39211670e3358976ae610240d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies</topic><topic>Antibodies, Neutralizing - blood</topic><topic>Antibodies, Viral - blood</topic><topic>Asymptomatic Infections</topic><topic>COVID-19</topic><topic>COVID-19 - blood</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines</topic><topic>Female</topic><topic>Health risks</topic><topic>Humans</topic><topic>Immunoassay</topic><topic>Immunoassays</topic><topic>Infections</topic><topic>Live VNT</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neutralization</topic><topic>Neutralization Tests</topic><topic>Neutralizing</topic><topic>SARS-CoV-2 - immunology</topic><topic>SARS-CoV-2 neutralizing antibodies</topic><topic>Serological immunoassay</topic><topic>Serology</topic><topic>Serum levels</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Strain analysis</topic><topic>Vaccination</topic><topic>Viral diseases</topic><topic>Viral infections</topic><topic>Viruses</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cristiano, Antonio</creatorcontrib><creatorcontrib>Nuccetelli, Marzia</creatorcontrib><creatorcontrib>Pieri, Massimo</creatorcontrib><creatorcontrib>Sarubbi, Serena</creatorcontrib><creatorcontrib>Pelagalli, Martina</creatorcontrib><creatorcontrib>Calugi, Graziella</creatorcontrib><creatorcontrib>Tomassetti, Flaminia</creatorcontrib><creatorcontrib>Bernardini, Sergio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cristiano, Antonio</au><au>Nuccetelli, Marzia</au><au>Pieri, Massimo</au><au>Sarubbi, Serena</au><au>Pelagalli, Martina</au><au>Calugi, Graziella</au><au>Tomassetti, Flaminia</au><au>Bernardini, Sergio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>101</volume><issue>Pt B</issue><spage>108215</spage><epage>108215</epage><pages>108215-108215</pages><artnum>108215</artnum><issn>1567-5769</issn><eissn>1878-1705</eissn><abstract>•Anti-SARS-CoV-2 serological assay correlation to live virus neutralization tests.•Antibodies levels were correlated to SARS-CoV-2 original and British variant strains.•A proportional increase in neutralizing activity and antibody concentration resulted.•Neutralizing antibodies detection is a good alternative to virus neutralization tests.•A cut-off of 408.6 BAU/ml can identify subjects at low risk of infection.
A large number of immunoassays have been developed to detect specific anti-SARS-CoV-2 antibodies; however, not always they are functional to neutralize the virus. The reference test for the anti-spike neutralizing antibodies (nAbs) ability to counteract the viral infection is the virus neutralization test (VNT). Great interest is developing on reliable serological assays allowing antibodies concentration and antibody protective titer correlation. The aim of our study was to detect nAbs serum levels in paucisymptomatic, symptomatic and vaccinated subjects, to find a cut-off value able to protect from virus infection.
nAbs serum levels were detected by a competitive automated immunoassay, in association to VNT with the SARS-CoV-2 original and British variant strains.
The median nAbs concentrations were: 281.3 BAU/ml for paucisymptomatics; 769.4 BAU/ml for symptomatics; 351.65 BAU/ml for the vaccinated cohort; 983 BAU/ml considering only the second dose vaccinated individuals. The original strain VNT analysis showed 1:80 median neutralization titers in paucisymptomatic and vaccinated subjects; 1:160 in symptomatic patients; 1:160 in the second dose groups. The British variant VNT analysis showed lower neutralization titers in paucisymptomatic and vaccinated groups (1:40); the same titer in symptomatic patients (1:160); the second dose group confirmed the original strain titer (1:160).
In conclusion, our data showed optimal correlations with a proportional increase between neutralizing activity and antibody concentration, making nAbs detection a good alternative to virus neutralization assays, difficult to carry out in routine laboratories. Finally, ROC curve analysis established a cut-off of 408.6 BAU/ml to identify subjects with a low risk of infection.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>34649115</pmid><doi>10.1016/j.intimp.2021.108215</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1567-5769 |
| ispartof | International immunopharmacology, 2021-12, Vol.101 (Pt B), p.108215-108215, Article 108215 |
| issn | 1567-5769 1878-1705 |
| language | eng |
| recordid | cdi_proquest_journals_2624986319 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adult Aged Aged, 80 and over Antibodies Antibodies, Neutralizing - blood Antibodies, Viral - blood Asymptomatic Infections COVID-19 COVID-19 - blood COVID-19 - immunology COVID-19 - prevention & control COVID-19 Vaccines Female Health risks Humans Immunoassay Immunoassays Infections Live VNT Male Middle Aged Neutralization Neutralization Tests Neutralizing SARS-CoV-2 - immunology SARS-CoV-2 neutralizing antibodies Serological immunoassay Serology Serum levels Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Strain analysis Vaccination Viral diseases Viral infections Viruses Young Adult |
| title | Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T04%3A26%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serological%20anti-SARS-CoV-2%20neutralizing%20antibodies%20association%20to%20live%20virus%20neutralizing%20test%20titers%20in%20COVID-19%20paucisymptomatic/symptomatic%20patients%20and%20vaccinated%20subjects&rft.jtitle=International%20immunopharmacology&rft.au=Cristiano,%20Antonio&rft.date=2021-12-01&rft.volume=101&rft.issue=Pt%20B&rft.spage=108215&rft.epage=108215&rft.pages=108215-108215&rft.artnum=108215&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2021.108215&rft_dat=%3Cproquest_pubme%3E2582812800%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2624986319&rft_id=info:pmid/34649115&rft_els_id=S1567576921008511&rfr_iscdi=true |